Quotient Limited Ord (QTNT) 7.86 $QTNT
Quotient Limited (QTNT) Catches Eye: Stock Jumps 9.8%
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:30AM CDT
Quotient Limited (QTNT) shares rose almost 10% in the last trading session.
QTNT: 7.86 (-0.09), EW: 119.77 (-1.10)
Quotient Limited Announces Successful Validation of the Initial Manufacturing System for MosaiQ(TM) Microarrays
GlobeNewswire - Thu Sep 08, 3:05PM CDT
-- MosaiQ manufacturing system operating in accordance with design requirements
QTNT: 7.86 (-0.09)
Quotient Limited Reports Further Progress on the Commercial Scale-up of MosaiQ(TM) and First Quarter Fiscal 2017 Financial Results
GlobeNewswire - Mon Aug 08, 3:15PM CDT
-- Facility modification completed - humidity control successfully resolved issue previously impacting final assembly of MosaiQ(TM) consumables
QTNT: 7.86 (-0.09)
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
GlobeNewswire - Wed Aug 03, 3:17PM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the closing of its underwritten public offering of 3,220,000 of its ordinary shares at a price to the public of $5.50 per share, which includes the exercise in full by the underwriter of its option to purchase up to 420,000 additional ordinary shares. The offering generated gross proceeds of approximately $17.7 with Quotient receiving net proceeds of approximately $16.3 million after deducting underwriting discounts and estimated offering expenses.
QTNT: 7.86 (-0.09)
Quotient Limited to Report First Quarter Fiscal 2017 Financial Results and Host Conference Call
GlobeNewswire - Mon Aug 01, 7:30AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ending June 30, 2016 will be released after market close on Monday, August 8, 2016.
QTNT: 7.86 (-0.09)
Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
GlobeNewswire - Fri Jul 29, 8:15AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the pricing of an underwritten public offering of 2,800,000 of its ordinary shares at a price to the public of $5.50 per share. The net proceeds to Quotient from this offering are expected to be $14.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Quotient. Quotient has also granted the underwriter a 30-day option to purchase up to an additional 420,000 of its ordinary shares. The offering is expected to close on or about August 3, 2016, subject to customary closing conditions.
QTNT: 7.86 (-0.09)
Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
GlobeNewswire - Thu Jul 28, 3:10PM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of its ordinary shares.
QTNT: 7.86 (-0.09)
Should You Get Rid of Quotient Limited (QTNT) Now?
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:43AM CDT
Quotient Limited has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
QTNT: 7.86 (-0.09), CRY: 18.14 (-0.42)
Quotient Limited to Participate in Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Tue May 31, 7:30AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company's Chairman & CEO, Paul Cowan, will present at the Jefferies 2016 Global Healthcare Conference in New York City at 2:00 p.m. Eastern Time on Wednesday, June 8. The presentation will be webcast live on the company's website at www.quotientbd.com.
QTNT: 7.86 (-0.09)
Quotient Limited Reports Continued Progress on the Development of MosaiQ(TM) and Fourth Quarter and Fiscal Year 2016 Financial Results
GlobeNewswire - Mon May 23, 3:17PM CDT
-- Completed commissioning of initial manufacturing system for MosaiQ consumables
QTNT: 7.86 (-0.09)
Quotient Limited to Report Fourth Quarter Fiscal 2016 Financial Results and Host Conference Call
GlobeNewswire - Wed May 11, 7:02AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal year ending March 31, 2016 will be released after market close on Monday, May 23, 2016.
QTNT: 7.86 (-0.09)
Quotient Limited to Participate in UBS Global Healthcare Conference
GlobeNewswire - Wed May 11, 6:59AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company's Chairman & CEO, Paul Cowan, will present at the UBS Global Healthcare Conference in New York City at 4:00 p.m. Eastern Time on Tuesday, May 24, 2016.
QTNT: 7.86 (-0.09)
Quotient Awarded UK's Highest Accolade for Business Success
PR Newswire - Thu Apr 21, 6:00AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that its UK subsidiary, Alba Bioscience Limited ("Alba"
, has been awarded the prestigious Queen's Award for Enterprise in the category of outstanding achievement in international trade. Alba develops, manufactures and commercializes products for the global transfusion diagnostics market.
QTNT: 7.86 (-0.09)
Quotient Limited Announces Estimated Third Quarter Fiscal 2016 Financial Results
GlobeNewswire - Wed Feb 03, 3:01PM CST
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced estimated financial results for its fiscal third quarter ended on December 31, 2015. Quotient's estimated financial results for the three months ended December 31, 2015 presented below are preliminary and are subject to the completion of its quarter-end closing procedures and financial review:
QTNT: 7.86 (-0.09)
Quotient Limited to Report Third Quarter Fiscal 2016 Financial Results and Host Conference Call
GlobeNewswire - Mon Feb 01, 7:00AM CST
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ending December 31, 2015 will be released before the market opens on Monday, February 8, 2016.
QTNT: 7.86 (-0.09)
Quotient Limited Announces Positive Serological Disease Screening Results and Provides MosaiQ(TM) Development Program Update
GlobeNewswire - Mon Jan 11, 6:01AM CST
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, will present the following update on the MosaiQ(TM) development program during its company presentation at the J.P. Morgan 2016 Healthcare Conference. MosaiQ(TM) is at an advanced stage of development and commercial scale-up and represents a truly novel testing platform for transfusion diagnostics. Current development efforts are focused on final assay optimization for the blood grouping and serological disease screening applications; commissioning the initial manufacturing system for MosaiQ(TM) consumables; and completing development of the MosaiQ(TM) instrument.
QTNT: 7.86 (-0.09), JPM: 67.25 (-0.14)
Quotient Limited to Expand Capability of Its MosaiQ(TM) Next-Generation Transfusion Diagnostics Platform to Include Nucleic Acid Testing
GlobeNewswire - Mon Jan 11, 6:00AM CST
-- Initial feasibility study demonstrates ability to detect nucleic acid using MosaiQ
QTNT: 7.86 (-0.09)
Quotient Limited (QTNT) Catches Eye: Stock Jumps 9.8%
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:30AM CDT
Quotient Limited (QTNT) shares rose almost 10% in the last trading session.
QTNT: 7.86 (-0.09), EW: 119.77 (-1.10)
Quotient Limited Announces Successful Validation of the Initial Manufacturing System for MosaiQ(TM) Microarrays
GlobeNewswire - Thu Sep 08, 3:05PM CDT
-- MosaiQ manufacturing system operating in accordance with design requirements
QTNT: 7.86 (-0.09)
Quotient Limited Reports Further Progress on the Commercial Scale-up of MosaiQ(TM) and First Quarter Fiscal 2017 Financial Results
GlobeNewswire - Mon Aug 08, 3:15PM CDT
-- Facility modification completed - humidity control successfully resolved issue previously impacting final assembly of MosaiQ(TM) consumables
QTNT: 7.86 (-0.09)
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
GlobeNewswire - Wed Aug 03, 3:17PM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the closing of its underwritten public offering of 3,220,000 of its ordinary shares at a price to the public of $5.50 per share, which includes the exercise in full by the underwriter of its option to purchase up to 420,000 additional ordinary shares. The offering generated gross proceeds of approximately $17.7 with Quotient receiving net proceeds of approximately $16.3 million after deducting underwriting discounts and estimated offering expenses.
QTNT: 7.86 (-0.09)
Quotient Limited to Report First Quarter Fiscal 2017 Financial Results and Host Conference Call
GlobeNewswire - Mon Aug 01, 7:30AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ending June 30, 2016 will be released after market close on Monday, August 8, 2016.
QTNT: 7.86 (-0.09)
Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
GlobeNewswire - Fri Jul 29, 8:15AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the pricing of an underwritten public offering of 2,800,000 of its ordinary shares at a price to the public of $5.50 per share. The net proceeds to Quotient from this offering are expected to be $14.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Quotient. Quotient has also granted the underwriter a 30-day option to purchase up to an additional 420,000 of its ordinary shares. The offering is expected to close on or about August 3, 2016, subject to customary closing conditions.
QTNT: 7.86 (-0.09)
Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
GlobeNewswire - Thu Jul 28, 3:10PM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of its ordinary shares.
QTNT: 7.86 (-0.09)
Should You Get Rid of Quotient Limited (QTNT) Now?
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:43AM CDT
Quotient Limited has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
QTNT: 7.86 (-0.09), CRY: 18.14 (-0.42)
Quotient Limited to Participate in Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Tue May 31, 7:30AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company's Chairman & CEO, Paul Cowan, will present at the Jefferies 2016 Global Healthcare Conference in New York City at 2:00 p.m. Eastern Time on Wednesday, June 8. The presentation will be webcast live on the company's website at www.quotientbd.com.
QTNT: 7.86 (-0.09)
Quotient Limited Reports Continued Progress on the Development of MosaiQ(TM) and Fourth Quarter and Fiscal Year 2016 Financial Results
GlobeNewswire - Mon May 23, 3:17PM CDT
-- Completed commissioning of initial manufacturing system for MosaiQ consumables
QTNT: 7.86 (-0.09)
Quotient Limited to Report Fourth Quarter Fiscal 2016 Financial Results and Host Conference Call
GlobeNewswire - Wed May 11, 7:02AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal year ending March 31, 2016 will be released after market close on Monday, May 23, 2016.
QTNT: 7.86 (-0.09)
Quotient Limited to Participate in UBS Global Healthcare Conference
GlobeNewswire - Wed May 11, 6:59AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company's Chairman & CEO, Paul Cowan, will present at the UBS Global Healthcare Conference in New York City at 4:00 p.m. Eastern Time on Tuesday, May 24, 2016.
QTNT: 7.86 (-0.09)
Quotient Awarded UK's Highest Accolade for Business Success
PR Newswire - Thu Apr 21, 6:00AM CDT
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that its UK subsidiary, Alba Bioscience Limited ("Alba"
, has been awarded the prestigious Queen's Award for Enterprise in the category of outstanding achievement in international trade. Alba develops, manufactures and commercializes products for the global transfusion diagnostics market. QTNT: 7.86 (-0.09)
Quotient Limited Announces Estimated Third Quarter Fiscal 2016 Financial Results
GlobeNewswire - Wed Feb 03, 3:01PM CST
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced estimated financial results for its fiscal third quarter ended on December 31, 2015. Quotient's estimated financial results for the three months ended December 31, 2015 presented below are preliminary and are subject to the completion of its quarter-end closing procedures and financial review:
QTNT: 7.86 (-0.09)
Quotient Limited to Report Third Quarter Fiscal 2016 Financial Results and Host Conference Call
GlobeNewswire - Mon Feb 01, 7:00AM CST
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ending December 31, 2015 will be released before the market opens on Monday, February 8, 2016.
QTNT: 7.86 (-0.09)
Quotient Limited Announces Positive Serological Disease Screening Results and Provides MosaiQ(TM) Development Program Update
GlobeNewswire - Mon Jan 11, 6:01AM CST
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, will present the following update on the MosaiQ(TM) development program during its company presentation at the J.P. Morgan 2016 Healthcare Conference. MosaiQ(TM) is at an advanced stage of development and commercial scale-up and represents a truly novel testing platform for transfusion diagnostics. Current development efforts are focused on final assay optimization for the blood grouping and serological disease screening applications; commissioning the initial manufacturing system for MosaiQ(TM) consumables; and completing development of the MosaiQ(TM) instrument.
QTNT: 7.86 (-0.09), JPM: 67.25 (-0.14)
Quotient Limited to Expand Capability of Its MosaiQ(TM) Next-Generation Transfusion Diagnostics Platform to Include Nucleic Acid Testing
GlobeNewswire - Mon Jan 11, 6:00AM CST
-- Initial feasibility study demonstrates ability to detect nucleic acid using MosaiQ
QTNT: 7.86 (-0.09)
